Pharm Flashcards
Aluminum chloride
topical antiperspirant: occludes eccrine and apocrine gland ducts
combines with keratin to produce fibrillar contraction
Tx: FIRST LINE hyperhidrosis
AE: irritation to broken skin
Botulinum toxin
injection: muscular paralysis
prevents vesicular and cell membrane fusion: SNARE cleavage
drug endocytosed
heavy chain binds cell membrane, light chain cleaves SNAP25
blocks release of painneuropeptides
Tx: hyperhidrosis
SECOND line
sprouting occurs: renews coupling between nerve and muscle
AE: systemic: respiratory arrest and death, anticholinergic effects, allergy to albumin
Glycopyrrolate
systemic antimuscarinic
Tx: hyperhidrosis
doesn’t cross BBB
AE: constipation, urinary retention, mydriasis, blurred vision, bronchiole dilation, tachycardia, decrease glandular secretion, restless, confusion, delirium, hallucinations
Oxybutynin
systemic antimuscarinic
cross BBB
Tx: hyperhidrosis
AE: constipation, urinary retention, mydriasis, blurred vision, bronchiole dilation, tachycardia, decrease glandular secretion, restless, confusion, delirium, hallucinations, SEDATION, DELIRIUM
Propantheline
systemic antimuscarinic
Tx: hyperhidrosis
doesn’t cross BBB
AE: constipation, urinary retention, mydriasis, blurred vision, bronchiole dilation, tachycardia, decrease glandular secretion, restless, confusion, delirium, hallucinations, DELIRIUM, SEDATION
Propranolol
reduce sympathetic CNS stimulation
Tx: hyperhidrosis
Clonidine
reduce sympathetic CNS
Tx: hyperhidrosis
Diltiazem
Ca channel involved in secretion process
Tx: hyperhidrosis
aldesleukin
IV, SC
IL-2 receptor stimulator
Tx: melanoma
CI: BBW CNS, BBW CARDIAC, BBW PULMONARY, BBW RENAL (CAPILLARY LEAK syndrome), hepatic, organ transplant
monitor: xray, thallium stress test (cardiac and pulm function)
dabrafenib
kinase inhibitor: BRAF (WT, V600E/K/D)
Tx: melanoma
diclofenac
topical chemical peel NSAIDs: PG inhibition unknown mechanism for actinic keratosis Tx: actinic keratosis AE: local skin
imiquimod
topical
activates TLR7/8 (Th1 response), adenosine receptor inhibitor, NFkB activation, negative GLI modulation (repress HH signaling)
Tx: basal cell carcinoma, actinic keratosis, HPV
CI: weakens physical barrier contraception protection
AE: photosensitivity, skin irritation (benzoyl alcohol, paraben)
interferon-alpha
IV, SC
activate CD8, NK to lyse tumor (perforin, granzyme, FasL)
Tx: melanoma
Caution in BBW: AUTOIMMUNE, CARDIAC, DEPRESSION
AE: flu-like, PULMONARY, BLOOD DYSCRASIA
monitor: xray, LFT, CBC, ECG
ipilimumuab
checkpoint inhibitor
CTLA4 inhibitor
Tx: melanoma
nivolumab
checkpoint inhibitor
PD-1 inhibitor
Tx: melanoma
pemolizumab
checkpoint inhibitor
PD-2 inhibitor
Tx: melanoma
sorafenib
kinase inhibitor
Tx: melanoma
AE: HTN
trametinib
kinase inhibitor: MEK1/2
Tx: melanoma
trichloroacetic acid
chemical peel
Tx: actinic keratosis
AE: localized SKIN (brun, inflammation, tender)
vemurafenib
kinase inhibitor: BRAF (V600E)
Tx: melanoma
vismodegib
HH pathway: SMO inhibitor
Tx: basal cell carcinoma
AE: intrauterine fetal death, TERATOGEN, ALOPECIA, GI
need contraception
hedgehog inhibitors
TERATOGEN
What type of skin cancer has no targeted therapies?
squamous cell
IL-2 receptor
differentiation and proliferation of T cells (b cells, monocytes, macrophages, CTLs)
CTLA4
negative regulator of T cell at initial T cell activation
binds CD80 and CD86 decreases the ability of CD80/86 to bind CD28
not on surface of: naive or memory T cells
maintains consistent level of T cells: after TCR encounters antigen CTLA is transported to surface (from vesicles): more stimulation means more CTLA4
PD-1/2
negative regulator of T cells: regulate inflammatory response by effector T cell
induces anergic state in T cells
Kinase inhibitors
oral
need genotype
potential teratogen
AE: SKIN, VASCULAR, HEART (QT prolongation), RENAL, EYE I
other: fatigue, GI, endocrine, heme, hepatic, cough, musculoskeletal, edema
avoid in PREGNANCY
MAPK/BRAF inhibitor resistance
different pathways
change in target
mutation downstream
cinoxate
sunscreen: chemical
UVB
Para-aminobenzoic acid (PABA)
sunscreen: chemical
UVB
trolamine
sunscreen: chemical
UVB
dioxybenzone
sunscreen: chemical
UVB, UVA2
oxybenzone
sunscreen: chemical
UVB, UVA2
avobenzone
sunscreen: chemical
all UVA
UVA
320-400 nm UVA1: 340-400 UVA2: 320-340 penetrates deep into skin to reach dermis indirect damage:
UVB
290-320 nm
direct DNA damage by linking pyrimidine bases
indirect damage:
titanium dioxide
sunscreen: inorganic physical
all UVA, UVB
micronized: does not provide UVA1
zinc dioxide
sunscreen: inorganic physical
all UVA, UVB
SPF
ability of sunscreen to protect skin from sunburn (UVB exposure)
NOT related to duration of exposure
UVB protection is not linear
FDA max: 50+ SPF for sunscreen
Can sunscreen be labeled waterproof?
no
water resistant only (maintains protection after 40-80 min of water immersion)
broadspectrum sunscreen
UVA and UVB protection
long extension of wavelengths covered
acyclovir
guanosine analog: inhibits viral DNA polymerase
monophosphorylated by viral thymidine kinase; triphosphate by host
virus lacks: 3’ OH
Tx: VZV
AE: cross hypersensitivity, SEIZURES (neurotoxic)
renal elimination: adjust does in renal disease
ganciclovir
guanosine analog
monophosphorylated by viral thymidine kinase; triphosphate by host
virus does not lack 3’ OH
Tx: HHV-6/7/8; actual HHV infection
AE: cross hypersensitivity, BLOOD DYSCRASIA, TERATOGEN
renal elimination: adjust does in renal disease
CI: immunosuppression be careful
cidofovir
cytosine analog: DNA polymerase inhibitor
Tx: Pox, HHV-6/7/8 (in vitro)
AE: NEPHROTOXIC
monitor: creatinine, probenecid hypersensitivity (reduce renal toxicity)
renal elimination: adjust does in renal disease
valacyclovir
oral
prodrug for acyclovir
Tx: VZV, HHV-8 (in vitro)
famciclovir
guanosine analog: inhibits viral DNA polymerase
monophosphorylated by viral thymidine kinase; triphosphate by host
Tx: VZV, HHV-8 (in vitro)
AE: cross hypersensitivity, no significant issues
renal elimination: adjust does in renal disease
valganciclovir
oral
prodrug for ganciclovir
Tx: HHV-6/8 (actual HHV-8 infection)
foscarnet
pyrophosphate binding site
DNA polymerase inhibitor; blocks chain elongation
Tx: HHV-6
AE: electrolytes imbalance, chelates Ca ions
renal elimination: adjust does in renal disease
amorolfine
topical only inhibits ergosterol synthesis Tx: fungal AE: hypersensitivity CI: PREGNANCY
ciclopirox
topical only
blocks fungal transmembrane transport, depleting essential substrates: interferes with RNA and DNA synthesis
Tx: fungal
AE: hypersensitive
naftifine
squalene 2,3 epoxidase inhibitor
locally bactericidal
Tx: fungal
anti-inflammatory: inhibit PG, LT, histamin: vasoconstriction
don’t combine with azole: diminishes effect
AE: hypersensitivity
fluconazole
crosses BBB
renal elimination
Tx: fungal
posaconazole
Tx: fungal
griseofulvin
oral, NO topical (can't penetrate) interferes with microtubule function, disrupts mitosis elimination: hepatic (also renal, sweat) CYP3A4 inducer Tx: fungal CI: PENICILLIN allergy, PREGNANCY AE: photosensitive, porphyria
terbinafine
inhibits squalene epoxidase hepatic metabolism/renal elimination Tx: fungal monitor: CBC, LFT can use in pregnancy AE: blood dyscrasia CI: immunosuppressed
itraconazole
Tx: fungal
AE: QT prolongation
voriconazole
Tx: fungal
imidazole class
-AZOLE inhibit 1,4-alpha-demethylase CYP3A4 substrate, inhibits CYPs hepatic elimination Tx: fungal CI: PREGNANCY AE: hepatotoxic
cefazolin
IV/IM 1st generation: beta lactamase resistant binds PBP: block cell wall cross linking Tx: uncomplicated skin infection adjust in renal failure AE: HYPERSENSITIVITY, SJS, eosinophilia
ceftaroline fosamil
5th generation
IV
binds PBPs
Tx: staph, strep; added Rx polymicrobial MRSA (when P. aeruginosa and anaerobic bacteria unlikely)
AE: constipation, hypokalemia, phlebitis, C. difficile, ELEVATED LFT, BLOOD DYSCRASIA
adjust in renal failure
monitor: CBC
cephalexin
PO 1st generation: beta lactamase resistant binds PBP: block cell wall cross linking Tx: staph, strep adjust in renal failure AE: HYPERSENSITIVITY, SJS
clindamycin
IV, IM
50s ribosomal inhibitor
Tx: uncomplicated skin infection if PCN allergy, CA-MRSA
AE: C-difficile infection, jaundice, SJS